Fasting conditions in clinical oncology trials and drug labelling - Authors' reply
Lancet Oncol
.
2017 Sep;18(9):e507.
doi: 10.1016/S1470-2045(17)30599-5.
Authors
Floor J E Lubberman
1
,
David Burger
2
,
Nielka P van Erp
2
Affiliations
1
Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands. Electronic address: floor.lubberman@radboudumc.nl.
2
Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands.
PMID:
28884695
DOI:
10.1016/S1470-2045(17)30599-5
No abstract available
Publication types
Letter
Comment
MeSH terms
Drug Labeling*
Fasting*
Medical Oncology